Acute retinal arterial occlusion after intravenous administration of bevacizumab

Retinal artery occlusions are usually the result of emboli, although non-embolic causes such as vasculitides, coagulopathies, and vasospasms resulting from migraines and inflammatory conditions do occur. Bevacizumab, a humanised monoclonal antibody, is designed to bind to and inhibit vascular endoth...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2009-05, Vol.2009 (may17 1), p.bcr0120091478-bcr0120091478
Main Authors: Artunay, Ozgur, Yuzbasioglu, Erdal, Rasier, Rifat, Sengul, Alper, Bahcecioglu, Halil
Format: Article
Language:English
Subjects:
Cancer therapies
Cardiovascular disease
Chemotherapy
Defects
Europe (East)
Health risk assessment
Lung cancer
Male
Medical personnel
Patients
Studies
Thromboembolism
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Vascular endothelial growth factor
White
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b4408-341e97d9d7693e95a524697d10c0622e65e622136caf79587a4911ab9ab64e5f3
cites
container_end_page bcr0120091478
container_issue may17 1
container_start_page bcr0120091478
container_title BMJ case reports
container_volume 2009
creator Artunay, Ozgur
Yuzbasioglu, Erdal
Rasier, Rifat
Sengul, Alper
Bahcecioglu, Halil
description Retinal artery occlusions are usually the result of emboli, although non-embolic causes such as vasculitides, coagulopathies, and vasospasms resulting from migraines and inflammatory conditions do occur. Bevacizumab, a humanised monoclonal antibody, is designed to bind to and inhibit vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in tumour angiogenesis, the formation of new blood vessels to the tumour. The use of bevacizumab has spread worldwide, but the drug related adverse events associated with its use have been reported in a few retrospective reviews. We report on a previously unpublished case of retinal artery occlusion following the use of systemic bevacizumab.
doi_str_mv 10.1136/bcr.01.2009.1478
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3029805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4029561081</sourcerecordid><originalsourceid>FETCH-LOGICAL-b4408-341e97d9d7693e95a524697d10c0622e65e622136caf79587a4911ab9ab64e5f3</originalsourceid><addsrcrecordid>eNqFkU1LxDAQhoMo7qLePUnBgwfZNdOkTXMRZPELFvSg4C2k2almaZs1aRf015uyKurFXGaYPPMyMy8hh0CnACw_K42fUpimlMopcFFskTGITEyEpE_bP_IROQhhSeNjwAvOdskohbwQFOiY3F-YvsPEY2dbXSfad-htTJwxdR-saxNdxVJi287rNbauD4leNLa1IRa6AXBVUuJaG_veN7rcJzuVrgMefMY98nh1-TC7mczvrm9nF_NJyTktJowDSrGQC5FLhjLTWcrzWABqaJ6mmGcYQ1zT6ErIrBCaSwBdSl3mHLOK7ZHzje6qLxtcGBwGrNXK20b7N-W0Vb9_Wvuint1aMZrKgmZR4ORTwLvXHkOnGhsM1rVuMW6pCsEgZUKISB7_IZeu9_FcQYEoUslZvGWk6IYy3oXgsfqeBagaDFPRMEVBDYapwbDYcvRzh--GL3sicLoBymb5v9wHwGmfdQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1782943701</pqid></control><display><type>article</type><title>Acute retinal arterial occlusion after intravenous administration of bevacizumab</title><source>PubMed (Medline)</source><creator>Artunay, Ozgur ; Yuzbasioglu, Erdal ; Rasier, Rifat ; Sengul, Alper ; Bahcecioglu, Halil</creator><creatorcontrib>Artunay, Ozgur ; Yuzbasioglu, Erdal ; Rasier, Rifat ; Sengul, Alper ; Bahcecioglu, Halil</creatorcontrib><description>Retinal artery occlusions are usually the result of emboli, although non-embolic causes such as vasculitides, coagulopathies, and vasospasms resulting from migraines and inflammatory conditions do occur. Bevacizumab, a humanised monoclonal antibody, is designed to bind to and inhibit vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in tumour angiogenesis, the formation of new blood vessels to the tumour. The use of bevacizumab has spread worldwide, but the drug related adverse events associated with its use have been reported in a few retrospective reviews. We report on a previously unpublished case of retinal artery occlusion following the use of systemic bevacizumab.</description><identifier>ISSN: 1757-790X</identifier><identifier>EISSN: 1757-790X</identifier><identifier>DOI: 10.1136/bcr.01.2009.1478</identifier><identifier>PMID: 21687010</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Cancer therapies ; Cardiovascular disease ; Chemotherapy ; Defects ; Europe (East) ; Health risk assessment ; Lung cancer ; Male ; Medical personnel ; Patients ; Studies ; Thromboembolism ; Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions ; Vascular endothelial growth factor ; White</subject><ispartof>BMJ case reports, 2009-05, Vol.2009 (may17 1), p.bcr0120091478-bcr0120091478</ispartof><rights>2009 BMJ Publishing Group Ltd</rights><rights>Copyright: 2009 2009 BMJ Publishing Group Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b4408-341e97d9d7693e95a524697d10c0622e65e622136caf79587a4911ab9ab64e5f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3029805/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3029805/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21687010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Artunay, Ozgur</creatorcontrib><creatorcontrib>Yuzbasioglu, Erdal</creatorcontrib><creatorcontrib>Rasier, Rifat</creatorcontrib><creatorcontrib>Sengul, Alper</creatorcontrib><creatorcontrib>Bahcecioglu, Halil</creatorcontrib><title>Acute retinal arterial occlusion after intravenous administration of bevacizumab</title><title>BMJ case reports</title><addtitle>BMJ Case Rep</addtitle><description>Retinal artery occlusions are usually the result of emboli, although non-embolic causes such as vasculitides, coagulopathies, and vasospasms resulting from migraines and inflammatory conditions do occur. Bevacizumab, a humanised monoclonal antibody, is designed to bind to and inhibit vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in tumour angiogenesis, the formation of new blood vessels to the tumour. The use of bevacizumab has spread worldwide, but the drug related adverse events associated with its use have been reported in a few retrospective reviews. We report on a previously unpublished case of retinal artery occlusion following the use of systemic bevacizumab.</description><subject>Cancer therapies</subject><subject>Cardiovascular disease</subject><subject>Chemotherapy</subject><subject>Defects</subject><subject>Europe (East)</subject><subject>Health risk assessment</subject><subject>Lung cancer</subject><subject>Male</subject><subject>Medical personnel</subject><subject>Patients</subject><subject>Studies</subject><subject>Thromboembolism</subject><subject>Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions</subject><subject>Vascular endothelial growth factor</subject><subject>White</subject><issn>1757-790X</issn><issn>1757-790X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkU1LxDAQhoMo7qLePUnBgwfZNdOkTXMRZPELFvSg4C2k2almaZs1aRf015uyKurFXGaYPPMyMy8hh0CnACw_K42fUpimlMopcFFskTGITEyEpE_bP_IROQhhSeNjwAvOdskohbwQFOiY3F-YvsPEY2dbXSfad-htTJwxdR-saxNdxVJi287rNbauD4leNLa1IRa6AXBVUuJaG_veN7rcJzuVrgMefMY98nh1-TC7mczvrm9nF_NJyTktJowDSrGQC5FLhjLTWcrzWABqaJ6mmGcYQ1zT6ErIrBCaSwBdSl3mHLOK7ZHzje6qLxtcGBwGrNXK20b7N-W0Vb9_Wvuint1aMZrKgmZR4ORTwLvXHkOnGhsM1rVuMW6pCsEgZUKISB7_IZeu9_FcQYEoUslZvGWk6IYy3oXgsfqeBagaDFPRMEVBDYapwbDYcvRzh--GL3sicLoBymb5v9wHwGmfdQ</recordid><startdate>20090517</startdate><enddate>20090517</enddate><creator>Artunay, Ozgur</creator><creator>Yuzbasioglu, Erdal</creator><creator>Rasier, Rifat</creator><creator>Sengul, Alper</creator><creator>Bahcecioglu, Halil</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090517</creationdate><title>Acute retinal arterial occlusion after intravenous administration of bevacizumab</title><author>Artunay, Ozgur ; Yuzbasioglu, Erdal ; Rasier, Rifat ; Sengul, Alper ; Bahcecioglu, Halil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b4408-341e97d9d7693e95a524697d10c0622e65e622136caf79587a4911ab9ab64e5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Cancer therapies</topic><topic>Cardiovascular disease</topic><topic>Chemotherapy</topic><topic>Defects</topic><topic>Europe (East)</topic><topic>Health risk assessment</topic><topic>Lung cancer</topic><topic>Male</topic><topic>Medical personnel</topic><topic>Patients</topic><topic>Studies</topic><topic>Thromboembolism</topic><topic>Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions</topic><topic>Vascular endothelial growth factor</topic><topic>White</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Artunay, Ozgur</creatorcontrib><creatorcontrib>Yuzbasioglu, Erdal</creatorcontrib><creatorcontrib>Rasier, Rifat</creatorcontrib><creatorcontrib>Sengul, Alper</creatorcontrib><creatorcontrib>Bahcecioglu, Halil</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Artunay, Ozgur</au><au>Yuzbasioglu, Erdal</au><au>Rasier, Rifat</au><au>Sengul, Alper</au><au>Bahcecioglu, Halil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute retinal arterial occlusion after intravenous administration of bevacizumab</atitle><jtitle>BMJ case reports</jtitle><addtitle>BMJ Case Rep</addtitle><date>2009-05-17</date><risdate>2009</risdate><volume>2009</volume><issue>may17 1</issue><spage>bcr0120091478</spage><epage>bcr0120091478</epage><pages>bcr0120091478-bcr0120091478</pages><issn>1757-790X</issn><eissn>1757-790X</eissn><abstract>Retinal artery occlusions are usually the result of emboli, although non-embolic causes such as vasculitides, coagulopathies, and vasospasms resulting from migraines and inflammatory conditions do occur. Bevacizumab, a humanised monoclonal antibody, is designed to bind to and inhibit vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in tumour angiogenesis, the formation of new blood vessels to the tumour. The use of bevacizumab has spread worldwide, but the drug related adverse events associated with its use have been reported in a few retrospective reviews. We report on a previously unpublished case of retinal artery occlusion following the use of systemic bevacizumab.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>21687010</pmid><doi>10.1136/bcr.01.2009.1478</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1757-790X
ispartof BMJ case reports, 2009-05, Vol.2009 (may17 1), p.bcr0120091478-bcr0120091478
issn 1757-790X
1757-790X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3029805
source PubMed (Medline)
subjects Cancer therapies
Cardiovascular disease
Chemotherapy
Defects
Europe (East)
Health risk assessment
Lung cancer
Male
Medical personnel
Patients
Studies
Thromboembolism
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Vascular endothelial growth factor
White
title Acute retinal arterial occlusion after intravenous administration of bevacizumab
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A26%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20retinal%20arterial%20occlusion%20after%20intravenous%20administration%20of%20bevacizumab&rft.jtitle=BMJ%20case%20reports&rft.au=Artunay,%20Ozgur&rft.date=2009-05-17&rft.volume=2009&rft.issue=may17%201&rft.spage=bcr0120091478&rft.epage=bcr0120091478&rft.pages=bcr0120091478-bcr0120091478&rft.issn=1757-790X&rft.eissn=1757-790X&rft_id=info:doi/10.1136/bcr.01.2009.1478&rft_dat=%3Cproquest_pubme%3E4029561081%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b4408-341e97d9d7693e95a524697d10c0622e65e622136caf79587a4911ab9ab64e5f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1782943701&rft_id=info:pmid/21687010&rfr_iscdi=true